Joshua A. Whitehill’s practice focuses on patent litigation and strategy in the fields of pharmaceuticals and biotechnology.

Josh has more than ten years of experience representing and counseling life science clients in patent and technology disputes in federal district court, patent office proceedings, arbitration, and appeals.  He has concentrated his practice on patent litigation relating to small molecules and biological products, including generic drug litigation under the Hatch-Waxman Act and biosimilar litigation under the Biologics Price Competition and Innovation Act (BPCIA).  Josh also has considerable experience advising biopharmaceutical companies on patent validity and infringement, pre-litigation strategy, patent and market landscapes, freedom to operate, and risk assessment and mitigation strategies.

Josh’s patent matters have involved a wide range of life sciences, including blockbuster and orphan drugs for oncology, immunology, gastroenterology, HIV, diabetes, cardiovascular disorders, men’s and women’s health, as well as gene-editing technologies, medical devices, and vaccines.  He has a degree in chemistry.

Josh’s pro bono activities include representing clients in administrative proceedings related to veteran benefits, naturalization, VAWA status, and permanent residency status.